Aeglea Bio Therapeutics (AGLE) Earns Coverage Optimism Rating of 0.17

News headlines about Aeglea Bio Therapeutics (NASDAQ:AGLE) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aeglea Bio Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.0099249761138 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

A number of equities analysts have weighed in on AGLE shares. Needham & Company LLC lifted their price objective on Aeglea Bio Therapeutics to $20.00 and gave the company a “buy” rating in a research note on Friday, April 13th. ValuEngine upgraded Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. Zacks Investment Research upgraded Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research note on Tuesday, May 15th. BMO Capital Markets started coverage on Aeglea Bio Therapeutics in a research note on Thursday, June 14th. They set an “outperform” rating and a $21.00 price objective for the company. Finally, Evercore ISI started coverage on Aeglea Bio Therapeutics in a research note on Tuesday, April 24th. They set an “outperform” rating and a $37.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, Aeglea Bio Therapeutics presently has an average rating of “Buy” and an average price target of $22.50.

Shares of NASDAQ AGLE traded up $0.24 during trading on Friday, reaching $10.72. 2,011,178 shares of the company traded hands, compared to its average volume of 256,189. The firm has a market capitalization of $229.08 million, a P/E ratio of -5.96 and a beta of 0.05. Aeglea Bio Therapeutics has a 12-month low of $2.81 and a 12-month high of $12.00.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.05). The company had revenue of $1.51 million for the quarter. Aeglea Bio Therapeutics had a negative net margin of 507.82% and a negative return on equity of 54.83%. sell-side analysts expect that Aeglea Bio Therapeutics will post -1.67 earnings per share for the current year.

In other Aeglea Bio Therapeutics news, major shareholder Bioventures Ltd Novartis sold 73,955 shares of Aeglea Bio Therapeutics stock in a transaction dated Thursday, May 10th. The stock was sold at an average price of $10.12, for a total transaction of $748,424.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 27.00% of the company’s stock.

Aeglea Bio Therapeutics Company Profile

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Insider Buying and Selling by Quarter for Aeglea Bio Therapeutics (NASDAQ:AGLE)

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply